Antibody-drug conjugates (ADCs) are becoming an increasingly relevant first-line treatment option for metastatic triple-negative breast cancer (TNBC). "ADCs are a fairly old class of drug that has really transformed the treatment of many different cancer types in the last 5 years or so," said Sheheryar Kabraji, BMBCh, chief of Breast Medicine at Roswell Park Comprehensive Cancer Center in Buffalo,...